PROKIDNEY CORP
PROKNASDAQ🏆 #2841 by market capEarnings Nov 9US Equity
$1.51▼ $0.02 (−0.99%)
Pre-market · at closeTrack PROK
Get earnings, price moves & breaking news on Telegram
24h▼ 1.0%
7d▲ 6.0%
14d▲ 3.8%
30d▼ 8.0%
ytd▼ 32.5%
1y▼ 51.7%
🏦Market Cap
$506M
Small Cap
📈Revenue Growth (YoY)
1075.0%
High Growth
📊Gross Margin
-252.6%
Thin
💵FCF Margin
-19527.4%
Thin
⚖️P/S Ratio
624.8x
Expensive
Otter Score
40
Weak
Trading Snapshot
- Day Range
- $1.46 – $1.59
- 52-Week Range
- $1.30 – $3.27
- Volume (shares)
- 96,232
- Avg Volume (shares)
- —
- Shares Outstanding
- 336.3M
- Next Earnings
- 2026-11-09
Fundamentals Snapshot
- Annual Revenue
- $893,000
- Last Q Revenue
- $150,000
- P/E Ratio
- -2.7
- P/S Ratio
- 624.8x
- EPS (TTM)
- $-0.46
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +9.7%
PROKIDNEY CORP
PROKFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$893K▲ +1075.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
100.0%▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$165M▼ −10.2% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$135M▼ −13.2% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
140.4M▲ +9.7% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$105M▲ +$9M YoY
StockOtter · stockotter.spaceAbout PROKIDNEY CORP
ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical evaluation; it is concurrently in Phase III and Phase II trials for individuals with moderate to severe diabetic kidney disease. Furthermore, the company is conducting a Phase I clinical trial to assess RAC-T's potential for patients born with congenital anomalies affecting the kidneys and urinary tract. The company was established in 2015 and operates from its headquarters in Winston-Salem, North Carolina.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
40/100
Analyst Ratings
ⓘConsensus
Buy
14 analysts
Strong Buy5
Buy4
Hold4
Sell1
Strong Sell0
Ratings as of Oct 2026
Latest News & Updates
News unavailable.